TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical Co. has announced the acquisition of 431,200 of its own shares at a total cost of 1,761,453,600 yen, conducted through open market discretionary trading on the Tokyo Stock Exchange. This move is part of a broader strategy approved by the board to acquire up to 3 million shares by the end of 2025, reflecting the company’s ongoing efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc., based in Tosu City, Saga Prefecture, is a company involved in the pharmaceutical industry. It focuses on the production and distribution of pharmaceutical products, with a notable presence in the market for common shares.
Average Trading Volume: 194,790
Technical Sentiment Signal: Sell
Current Market Cap: Yen297.1B
See more insights into 4530 stock on TipRanks’ Stock Analysis page.